Skip to main content
Fig. 2 | Acta Neuropathologica Communications

Fig. 2

From: Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis

Fig. 2

The objective response rate of sonidegib and vismodegib in MB patients. SMO inhibitors in relapsed MB were analysed using Reviewer Manager 5.3 software. No efficacy in non-SHH subtype of MB for either agent was detected. While the pooled ORR of sonidegib and vismodegib was 55 and 17% among MBSHH patients, respectively

Back to article page
\